These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 16166997)

  • 1. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 2. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 3. Slow start to phase 0 as researchers debate value.
    Twombly R
    J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
    [No Abstract]   [Full Text] [Related]  

  • 4. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor drug screening at the National Cancer Institute, U.S.A].
    Tsuruo T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2809-15. PubMed ID: 3310904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
    Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing new agents for the treatment of childhood cancer.
    Kurmasheva R; Morton C; Houghton PJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive trials receive boost.
    Jones D
    Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
    [No Abstract]   [Full Text] [Related]  

  • 9. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on NCI in vitro drug screen utilities.
    Holbeck SL
    Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
    Crowell JA
    Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug development in paediatric oncology].
    Benninger-Döring G; Boos J
    Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing access to investigational drugs.
    Christian M
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):90-1. PubMed ID: 16163167
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NCI Developmental Therapeutics Program.
    Collins JM
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinued drugs in 2008: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.